500257: Expansion In United States Operations Will Drive Long-Term Upside

Analysts have raised their price target for Lupin from ₹2,224.81 to ₹2,255.81. This reflects updated expectations around growth and margin assumptions.

Shared on 05 Sep 25

With both consensus revenue growth forecasts and future P/E estimates for Lupin remaining steady, analysts have left their fair value price target unchanged at ₹2225. What's in the News Lupin launched multiple generic drugs in the US, including Bosentan Tablets for Oral Suspension (first-to-file status), Glucagon for Injection, Loteprednol Etabonate Ophthalmic Suspension, Prucalopride Tablets, Ipratropium Bromide Nasal Solution, and secured FDA approvals for Liraglutide Injection and Oxcarbazepine Extended-Release Tablets.

Shared on 01 May 25

Fair value Decreased 5.04%

Shared on 23 Apr 25

Fair value Decreased 0.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.13%

AnalystConsensusTarget has decreased revenue growth from 9.7% to 6.1%, decreased profit margin from 16.0% to 14.2% and increased future PE multiple from 32.2x to 40.2x.